The Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2026 aims to lower insulin costs by capping out-of-pocket expenses, increasing transparency in pharmacy benefit management, accelerating generic and biosimilar competition, and expanding access for the uninsured.
Jeanne Shaheen
Senator
NH
The Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2026 aims to lower insulin costs by capping out-of-pocket expenses for insured patients and mandating transparency in pharmacy benefit manager rebates. The legislation also seeks to increase market competition by accelerating the approval of generic and biosimilar drugs. Additionally, it establishes a pilot program and national resource center to improve insulin affordability and access for uninsured individuals.
INSULIN Act of 2026 Caps Monthly Costs at $35 and Targets Middleman Fees to Lower Drug Prices
The INSULIN Act of 2026 is a major overhaul of how one of the world’s most essential medications is priced and sold in America. Starting in 2027, the bill mandates that most private health plans cover at least one of every major type of insulin (like rapid-acting or long-acting) with a hard out-of-pocket cap of $35 for a 30-day supply. Perhaps most importantly for your wallet, the bill bans insurance companies from applying deductibles to these products. This means if you’re a freelance coder or a retail manager on a high-deductible plan, you won’t have to shell out thousands of dollars in January before your coverage actually kicks in; the $35 price tag applies from day one of the plan year (Title I, Sec. 101).
Cutting Out the Middleman
Beyond the pharmacy counter, the bill takes a swing at the 'black box' of drug pricing by targeting Pharmacy Benefit Managers (PBMs). Currently, PBMs negotiate massive rebates from drug makers but often keep a slice of that cash for themselves. This legislation requires PBMs to pass 100% of those insulin rebates directly back to the health plans within 90 days (Title II). For a small business owner providing health insurance to twenty employees, this transparency could lead to lower overall premiums because the plan—not the middleman—is finally seeing the full savings negotiated behind the scenes.
Boosting Competition and Speed
To keep prices down long-term, the bill focuses on getting cheaper generic and biosimilar versions of insulin onto shelves faster. It cracks down on 'delay tactics' by requiring companies to file legal challenges within 60 days of getting new info, rather than waiting until a competitor is about to launch (Title III). It also gives the FDA a green light to fast-track reviews for biosimilars in markets where there are fewer than three competitors. Think of it like adding more lanes to a highway; more options usually mean less congestion and lower prices for the people driving the economy.
Safety Nets for the Uninsured
For those currently living without insurance, the bill sets up a five-year pilot program in ten states to provide insulin for no more than $35. It also establishes a 24/7 national hotline and resource center to help people navigate the often-confusing web of manufacturer assistance programs (Title IV). While brand-name drug makers and PBMs might see a hit to their bottom line due to increased competition and lost rebate revenue, the bill’s primary focus is ensuring that a person working a construction site or running a local shop doesn't have to choose between their groceries and their life-saving medication.